News

A survey of healthcare payers from North Highland offers four revealing findings about decision makers’ insights for the future.

 A new non-small cell lung cancer (NSCLC) treatment is available to healthcare providers immediately.  

A new report explores how healthcare executives can equip their healthcare organizations to make informed decisions about what type of reimbursement risk to take on.

After an expanded recall of the blood pressure medication valsartan, FDA is warning the manufacturer of the carcinogenic ingredient involved.

Walgreens' new integrated support program aims to help patients with cancer manage the side effects of undergoing treatment. Here’s five things to know about it.

As pharmaceuticals grow to consume more and more of the healthcare dollar, traditional care models need to change in order to deliver the best healthcare outcomes and real value. Here are five new models on the rise.

New research from Cardinal Health Specialty Solutions has surprising findings about oncologists from meeting MACRA requirements to burnout.

A new study of Medicaid-enrolled children with disabilities has revealing findings about the impact of care coordinator services on caregivers.

We asked the Managed Healthcare Executive editorial advisory board: “What is your New Year’s resolution and how do you plan to achieve it?” Here’s what they said.

In an effort to lower prescription drug prices, CMS unveiled proposed polices for 2020 to strengthen and modernize the Medicare Part C and D programs. Here’s a closer look at what CMS’ provisions entail and how they help accomplish the Administration’s four strategies.

Medicare Advantage enrollees can expect new benefits with the start of 2019. Here's what healthcare executives should know.

Two major drug recalls in the last week include an expanded recall of a widely used blood pressure medication as well as over-the-counter infant ibuprofen.

Find out how healthcare organizations and analysts feel about new Medicare Part D proposals and drug pricing.

Managed Healthcare Executive polled executives from across the industry to see how they feel about the current state-and future of-healthcare. 

While healthcare is often taken for granted in urban communities, many rural populations struggle to access care. Here’s how one healthcare organization addresses rural impediments and their effects on health.

Here’s how experts predict healthcare will unfold in 2019.

The combination of one of the country’s largest insurers and one of the country’s largest pharmacy chains will dramatically reshape the healthcare industry.

Growing up in in Limerick, Ireland, Michael J. Dowling admits his family situation was a little complicated-his mother was deaf and his father suffered from heart disease and arthritis. Read more about his early life and what led to his rise in healthcare.

The Integrated COPD Care Initiative in Alabama aims to reduce hospital readmission rates and acute to post-acute care-associated costs in COPD patients. Here are the results so far and insight from one of the program’s leaders.

FDA approved the first biosimilar to rituximab (Rituxan, Genentech) to treat non-Hodgkin lymphoma.

Evidence grows that these nonclinical factors have a large influence on patient outcomes. Here’s what hospitals and payers can do about it.

Here are ways healthcare execs can increase cancer awareness efforts.

A Managed Healthcare Executive’s cancer management survey revealed support for the selected use of complementary and alternative medicine. Where do things stand in what some consider a promising treatment area?

COPD is a chronic, progressive disorder that can lead to early death. Here are some ways to help mitigate the risk of developing this debilitating disorder.

The biosimilar market is flourishing in Europe-why aren’t we seeing similar gains in the U.S.?

As we look to the next year we can expect to see a few of these challenges settle, while others will continue to make headlines. Here are three things healthcare executives should watch.

In these arrangements, drug companies must partially reimburse insurers if the drug fails to earn its keep. Will COPD drugs be included in such arrangements?

The books healthcare executives recommend to other healthcare executives.